上海交通大学学报(医学版) ›› 2018, Vol. 38 ›› Issue (4): 411-.doi: 10.3969/j.issn.1674-8115.2018.04.010

• 论著·临床研究 • 上一篇    下一篇

基因1型HCV/HIV共同感染患者直接抗病毒药物预存耐药突变流行情况分析

蒋玲玉 1*,李雨浓 1*,胡鹏 2*,佘莎 1,张振芳 1   

  1. 1. 教育部感染性疾病分子生物学重点实验室,重庆医科大学病毒性肝炎研究所,重庆400016;2. 四川省成都市郫县中医医院检验科,成都611730
  • 出版日期:2018-04-28 发布日期:2018-05-03
  • 通讯作者: 张振芳,电子信箱:yishengzzf@163.com。
  • 作者简介:蒋玲玉(1991—),女,硕士生;电子信箱:329397054@qq.com。李雨浓(1992—),女,硕士生;电子信箱:3080955257@qq.com。胡鹏(1990—),男,检验技师,学士;电子信箱:641672006@qq.com。*为共同第一作者。
  • 基金资助:
    国家科技重大专项(2017ZX10202203-007,2017ZX10202203-008)

Prevalence of pre-existing direct-acting antiviral agents resistance-associated variants in genotype 1HCV/HIV co-infected patients

JIANG Ling-yu1*, LI Yu-nong1*, HU Peng2*, SHE Sha1, ZHANG Zhen-fang1   

  1. 1. Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral, Chongqing Medical University, Chongqing 400016, China;2. Department of Laboratory Medicine, Chengdu Pi County Traditional Chinese Medicine Hospital in Sichuan Province, Chengdu 611730, China
  • Online:2018-04-28 Published:2018-05-03
  • Supported by:
    National Science and Technology Major Project of China,2017ZX10202203-007,2017ZX10202203-008

摘要: 目的·探究基因1型丙型肝炎病毒(hepatitis C virus,HCV)/人类免疫缺陷病毒(human immunodeficiency virus,HIV)共同感染患者直接抗病毒药物(direct-acting antiviral agents,DAAs)预存耐药突变流行情况,以期对这一特殊群体的耐药情况有所了解。方法·通过美国国家生物技术信息中心(NCBI)核酸数据库进行数据挖掘,找出全部基因1型HCV/HIV共同感染患者的NS3和NS5B序列。然后用MEGA 5.0软件进行序列的比对和耐药分析。结果·总体来讲,无论基因1a型还是基因1b型,HCV/HIV共同感染患者NS3区的预存耐药突变流行率高(分别是26.06% 和38.18%)。在基因1a型患者中,高耐药相关突变主要出现在Q80上(8.45%);而在基因1b型患者中,S122耐药突变最为常见(36.36%)。在NS5B区的预存耐药突变罕见(0.77%),尤其是在基因1a型患者中,没有1条序列检测到耐药相关突变。结论·基因1型HCV/HIV共同感染患者NS3区的预存耐药突变流行率高,但NS5B区的预存耐药突变罕见。对HCV/HIV共同感染这一特殊群体使用DAAs治疗时,以NS5B抑制剂为基础的联合方案是很有必要的。

关键词: 丙型肝炎病毒, 共同感染, 直接抗病毒药物, 耐药相关突变, 流行率

Abstract:

Objective · To investigate the prevalence of pre-existing direct-acting antiviral agents (DAAs) resistance associated variants (RAVs) in genotype 1 hepatitis C virus (HCV)/ human immunodeficiency virus (HIV) co-infected patients. Methods · All NS3 and NS5B HCV sequences in genotype 1 HCV/HIV co-infected patients were retrieved NCBI GenBank database. And sequences were aligned and analyzed using software MEGA 5.0. Results · In total, the overall prevalence of DAAs RAVs in NS3 region was high (26.06% and 38.18%, respectively), no matter in genotype 1a or genotype 1b. In genotype 1a, the high prevalence of RAVs mainly presented in the position Q80 (8.45%). In genotype 1b, S122 RAV was most observed(36.36%). It is worth noting that, RAVs in NS5B region were rare observed (0.77%) in this study, especially as no RAV was detected in any sequence of genotype 1a patients. Conclusion · The prevalence of pre-existing RAVs is high in NS3 region but rare in NS5B region in HCV/HIV co-infected patients, suggesting that NS5B inhibitors based combination regions are a better choice for HCV/HIV co-infected patients.

Key words: hepatitis C virus, co-infection, direct-acting antiviral agents, resistance associated variants, prevalence

中图分类号: